Vincerx Pharma Stock (NASDAQ:VINC)
Previous Close
$1.65
52W Range
$1.48 - $187.44
50D Avg
$4.26
200D Avg
$10.96
Market Cap
$3.49M
Avg Vol (3M)
$400.52K
Beta
1.27
Div Yield
-
VINC Company Profile
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
VINC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CHRS | Coherus BioSciences, Inc. |
| SRZN | Surrozen, Inc. |
| PCSA | Processa Pharmaceuticals, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| SNTI | Senti Biosciences, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| LVTX | LAVA Therapeutics N.V. |
| RZLT | Rezolute, Inc. |
| TARA | Protara Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| XOMA | XOMA Corporation |
| BCAB | BioAtla, Inc. |
| APLT | Applied Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |